Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics disclosed that its FY2025 consolidated revenue increased by 30.3% year-on-year to approximately KRW 4.56T and operating profit rose 56.6% to KRW 2.07T, driven by full operation of Plant 4 and stable operations at Plants 1-3.
📊 [Key Disclosure Details & Financial Figures]
- Financial Statement Type: Consolidated Financial Statements (Unaudited preliminary figures)
- Fiscal Period: January 1, 2025 – December 31, 2025 (FY2025)
- Income Structure Changes (Original KRW units):
- Revenue: KRW 4,556,971,695,000 (KRW 4.56T / Prior Year: KRW 3,497,145,676,000 / Change: +KRW 1,059,826,019,000, +30.3%)
- Operating Profit: KRW 2,069,221,267,000 (KRW 2.07T / Prior Year: KRW 1,321,366,381,000 / Change: +KRW 747,854,886,000, +56.6%)
- Profit Before Tax: KRW 2,118,631,253,000 (KRW 2.12T / Prior Year: KRW 1,384,868,830,000 / Change: +KRW 733,762,423,000, +53.0%)
- Net Profit: KRW 1,614,330,309,000 (KRW 1.61T / Prior Year: KRW 1,040,301,541,000 / Change: +KRW 574,028,768,000, +55.2%)
- Key Causes of Change: Continued stable operation of Plants 1–3, along with increased revenue contributions from the full operation of Plant 4.
- Financial Position (Original KRW units):
- Total Assets: KRW 11,060,741,977,000 (Prior Year: KRW 17,336,296,350,000)
- Total Liabilities: KRW 3,609,631,329,000 (Prior Year: KRW 6,431,620,287,000)
- Total Equity: KRW 7,451,110,648,000 (Prior Year: KRW 10,904,676,062,000)
- Capital Stock: KRW 115,727,378,000 (Prior Year: KRW 177,935,000,000)
- Separate Financial Performance Revenue: KRW 4,556,971,695,000
- Board Resolution Date: January 21, 2026 (4 outside directors attended, 0 absent)
- Other Important Investment Details:
- Figures are preliminary prepared prior to the completion of external audit and are subject to change.
- Income figures for current and prior periods exclude discontinued operations profit/loss from Samsung Bioepis due to spin-off (FY2024: KRW 43.01B, FY2025: KRW 170.02B).
- Current financial position figures exclude Samsung Bioepis, while prior period financial position figures include Samsung Bioepis as they reflect pre-spin-off status.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Comparing Unaudited Preliminary Results with Final Figures in Upcoming Audit Report
Because this disclosure presents preliminary settlement results prior to the completion of the external audit, financial figures may be adjusted upon audit completion.
Checking for potential discrepancies between these preliminary figures and the final audited numbers in the upcoming audit report is crucial for verifying the ultimate accuracy of the financial performance.
Finalized details can be verified in the subsequent ‘Audit Report Submission’ disclosure.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial recommendations rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
